App-Quantinova.ai

Lower Prehospital Blood Pressure Is Not Associated with Larger Infarct Volumes in Non-lacunar Ischemic Stroke Patients

Laura C Gioia - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

N/A

Cerebral Blood Flow Threshold for Infarction After 3 Hours of Ischemia Determined in a Porcine Model of Stroke

Christopher -Esterre - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Coronary Artery Disease

endothelin-1

Low Cerebral Blood Flow (CBF) at Baseline Best Predicts Parenchymal Hematoma (PH) Post Revascularization Therapy

Connor McDougall - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Ischemic stroke

N/A

Analysis of Workflow and Time to Treatment in the Swift Prime Randomized Controlled Trial

Ashutosh P Jadhav - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Efficacy of Stent-retriever Thrombectomy in MRI Vs. CT Perfusion Selected Patients in SWIFT PRIME

Hopital Gui-de-Chauliac - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

Final Infarct Volume as an Early Indicator the Clinical Outcome: Insight from ESCAPE Trial

Mayank Goyal - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

N/A

Whole Brain CT Perfusion Identifies Ischemic Events in Patients With Mild Neurological Symptoms

Santanu Chakraborty - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Ischemic stroke

N/A

24-hour Infarct Volume on Non-contrast CT as a Predictor of Functional Outcome at 90 days

Matthew MacCormick - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

Grade 2 or Partial Collaterals in IMS III: Half Full or Half Empty?

Michael D Hill - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Ischemic stroke

N/A

Earlier Treatment is Associated with Higher Reperfusion Rates and Better Outcomes in the SWIFT PRIME Trial

Jeffery Saver - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

Effect of Solitaire Retriever-predominant Thrombectomy in Acute Ischemic Stroke: a Pooled, Individual Patient Data, Systematic Analysis

Jeffrey L Saver - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

N/A

The Role of Intravenous Thrombolysis in Patients With Acute Ischemic Stroke Treated With Mechanical Thrombectomy

David S. Liebeskind - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Intracerebral hemorrhage

N/A

Nox5 Induces Vascular Dysfunction and Arterial Remodelling Independently of Blood Pressure Elevation in Ang II-infused Nox5-expressing Mice

Adam P Harvey - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Angiology

Vasodilation dysfunction

Fasudil

Equitable Improvements in Sex and Race/Ethnic Specific Door-to-Needle Times in Acute Ischemic Stroke: Findings From Target: Stroke Phase I

Xin Zhao - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

N/A

Improving Door-to-Needle Times in Acute Ischemic Stroke: Interim Findings From Target: Stroke Phase II

Margueritte Cox - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

N/A

Somitic Mesoderm-derived and Sox2+ Stem Cells Give Rise To Sca-1+ Progenitor Cells in Mouse Aorta

Angela Li - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Tamoxifen

ABCA1 Response to Atherogenic Lipid Exposure is Reduced in Cultured Human Aortic Smooth Muscle Cells Compared to Human Monocyte-Derived Macrophages

Sima Allahverdian - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Effect of Idarucizumab on Intracranial Bleeding in Dabigatran-treated Patients: Initial Results From RE-VERSE AD

Charles V Pollack - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Non-valvular atrial fibrillation

Idarucizumab

ABCA1 Agonist Treatment of ApoE4 Driven Alzheimer-s Disease, Effects on Serum ApoE Distribution, Brain Phenotype and Cognition

Anat Boehm-Cagan - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

LDL Transcytosis by SR-BI Requires Signaling That is Distinct From Reverse Cholesterol Transport

Dante Neculai - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Nitric oxide

Filters

28841 Abstracts